Showing results (61-70 of 71) with videos related to
Sort By:
Pageof 8
British Journal of Haematology|December 6, 2019
Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapyDaniel J Landsburg, Emily C Ayers, David A Bond, et al.Cancer Letters|November 22, 2024
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profilingLorenzo Gerratana, Andrew A Davis, Lorenzo Foffano, et al.JCO Precision Oncology|May 4, 2023
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker AnalysisLorenzo Gerratana, Andrew A Davis, Marko Velimirovic, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast CancerWhitney L Hensing, Lorenzo Gerratana, Katherine Clifton, et al.Oncogene|January 26, 2018
A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancerDamiano Fantini, Alexander P Glaser, Kalen J Rimar, et al.Ebiomedicine|November 4, 2022
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerAndrew A Davis, Lorenzo Gerratana, Katherine Clifton, et al.The Journal of Molecular Diagnostics : JMD|December 15, 2019
Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in CancerDeepika Sirohi, Robert L Schmidt, Dara L Aisner, et al.British Journal of Haematology|July 30, 2016
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiableDaniel J Landsburg, Marissa K Falkiewicz, Adam M Petrich, et al.Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete RemissionDaniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, et al.Pageof 8